Novavax Inc. NVAX, +9.94% said Tuesday that one million doses of its protein-based COVID vaccine Nuvaxovid are now available in the U.K. “With U.K. data showing that people infected with both COVID-19 and the flu are more than five times as likely to die compared to someone with no infection(1) , it is more important than ever to consider any vaccine offered to you by the National Health Service,” said Stanley C. Erck, Novavax chief executive, in a statement. The Novavax vaccine uses more conventional technology than the mRNA-based ones developed by Pfizer PFE, +0.87%, BioNTech BNTX, +3.83% and Moderna MRNA, +3.66%, that were first to be approved and used widely in the pandemic. Shares were up 4.4% premarket but have fallen 87% in the year to date, while the S&P 500 SPX, +1.00% has fallen 23%.
